Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic drug research while providing patient data for iSTRYM, Mind Cure’s digital therapeutics platform. VANCOUVER, BC – January 12, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure” or the “Company”) is pleased to […]
Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research
Mind Cure’s iSTRYM (pronounced eye-stream) has been designed to warehouse the largest collection of psychedelic research and ongoing mental optimization data. With machine learning deployed, iSTRYM will provide greater speed to Mind Cure’s research team, richer data to health professionals and clients, as well as a hub of protocol and procedural information for psychedelic practitioners […]
Mind Cure Announces its Research Program with Psychedelic Compounds
The company is focused on investigating Psilocybin, Ketamine and Ibogaine compounds to be used in the treatment of physical and psychological pain and related mental health illnesses Vancouver, BC – December 8, 2020 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (DTC: MCURF) (“Mind Cure” or the “Company”) is pleased today to announce […]
Mind Cure Announces Eligibility for DTC Trading
Mind Cure’s common shares now able to meet US demand with more simplicity Vancouver, BC – Decemeber 2, 2020 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure” or the “Company”) is pleased today to announce that its common shares are now eligible for electronic clearing and settlement through the […]
